Thursday, 17 February 2011

Cannabinoid receptor signaling in neurodegenerative diseases: a potential role for membrane fluidity disturbance


Source the British Journal of Pharmacology:


Type-1 cannabinoid receptor (CB1) is the most abundant G-protein-coupled receptor (GPCR) in the brain. CB1and its endogenous agonists, the so-called “endocannabinoids (eCBs)”, belong to an ancient neurosignaling system that plays important functions in neurodegenerative and neuroinflammatory disorders like Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis. For this reason, research on the therapeutic potential of drugs modulating the endogenous tone of eCBs is very intense. Several GPCRs reside within subdomains of the plasma membranes that contain high concentrations of cholesterol: the lipid rafts.

Read more here.